Palatin's stock rockets after FDA OK to market sexual desire disorder treatment - MarketWatch
- Palatin's stock rockets after FDA OK to market sexual desire disorder treatment MarketWatch
- FDA erred on women's libido drug; don't reward Palatin Technologies STAT
- Regulators approve shot to boost women's sex drive New York Post
- Palatin Jumps Then Pulls Back After FDA Clears Sexual-Desire Drug for Women TheStreet.com
- Why This New FDA-approved Drug Vyleesi Is Not 'Female Viagra' Forbes
- View full coverage on Google News